A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
- on behalf of the HERIZON-BTC-01 study group
- Memorial Sloan-Kettering Cancer Center
- Zhongshan Hospital
- Seoul National University
- Yonsei University
- University of Ulsan
- Hubei Cancer Hospital
- Vall d'Hebron Institute of Oncology
- Naval Medical University
- CHU de Brest
- Zhejiang Cancer Hospital
- University College London
- AdventHealth
- Oregon Health and Science University
- Pusan National University
- Imperial College Healthcare NHS Trust
- Institut Gustave Roussy
- BeiGene
- Cholangiocarcinoma Foundation
- AMMF–The Cholangiocarcinoma Charity
- Zymeworks, Inc.
- Jazz Pharmaceuticals
- University of Texas MD Anderson Cancer Center
Research output: Contribution to journal › Article › peer-review
3
Scopus
citations